| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 53 | 2024 | 2638 | 4.820 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 89 | 2024 | 6550 | 4.760 |
Why?
|
| Transplantation Conditioning | 46 | 2023 | 2238 | 2.850 |
Why?
|
| Leukemia, Myeloid, Acute | 24 | 2023 | 6915 | 1.590 |
Why?
|
| Myeloablative Agonists | 8 | 2021 | 384 | 1.530 |
Why?
|
| Hematologic Neoplasms | 17 | 2022 | 1870 | 1.420 |
Why?
|
| Myelodysplastic Syndromes | 15 | 2021 | 2979 | 1.330 |
Why?
|
| Multiple Myeloma | 21 | 2023 | 2138 | 1.170 |
Why?
|
| Transplantation, Homologous | 42 | 2023 | 2843 | 1.150 |
Why?
|
| Cyclophosphamide | 18 | 2024 | 3001 | 1.060 |
Why?
|
| Cord Blood Stem Cell Transplantation | 7 | 2018 | 362 | 1.050 |
Why?
|
| Stem Cell Transplantation | 17 | 2021 | 1360 | 1.010 |
Why?
|
| Transplantation, Autologous | 26 | 2023 | 1914 | 0.970 |
Why?
|
| Busulfan | 8 | 2021 | 764 | 0.810 |
Why?
|
| Lymphocyte Depletion | 3 | 2018 | 264 | 0.790 |
Why?
|
| Antilymphocyte Serum | 5 | 2022 | 228 | 0.780 |
Why?
|
| Transplants | 1 | 2021 | 52 | 0.780 |
Why?
|
| Histocompatibility Testing | 5 | 2018 | 447 | 0.700 |
Why?
|
| Melphalan | 16 | 2019 | 834 | 0.680 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 82 | 0.630 |
Why?
|
| Vidarabine | 16 | 2019 | 1341 | 0.600 |
Why?
|
| Aged | 81 | 2024 | 70117 | 0.570 |
Why?
|
| Body Fluids | 1 | 2017 | 125 | 0.570 |
Why?
|
| Recurrence | 21 | 2023 | 4758 | 0.550 |
Why?
|
| Edema | 1 | 2017 | 267 | 0.530 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 755 | 0.520 |
Why?
|
| Middle Aged | 95 | 2021 | 86204 | 0.520 |
Why?
|
| Tissue Donors | 8 | 2022 | 769 | 0.500 |
Why?
|
| Adult | 84 | 2024 | 77950 | 0.480 |
Why?
|
| Weight Gain | 1 | 2017 | 464 | 0.480 |
Why?
|
| Allografts | 8 | 2021 | 650 | 0.480 |
Why?
|
| Survival Analysis | 22 | 2021 | 9180 | 0.460 |
Why?
|
| Humans | 125 | 2024 | 261506 | 0.460 |
Why?
|
| Methylprednisolone | 2 | 2011 | 193 | 0.450 |
Why?
|
| T-Lymphocytes | 5 | 2018 | 3869 | 0.450 |
Why?
|
| Retrospective Studies | 50 | 2024 | 37905 | 0.440 |
Why?
|
| Tacrolimus | 5 | 2022 | 335 | 0.430 |
Why?
|
| Disease-Free Survival | 28 | 2021 | 10001 | 0.430 |
Why?
|
| Histocompatibility | 5 | 2022 | 168 | 0.420 |
Why?
|
| Unrelated Donors | 5 | 2023 | 304 | 0.410 |
Why?
|
| Antibodies, Monoclonal | 10 | 2012 | 4367 | 0.410 |
Why?
|
| Male | 88 | 2023 | 123000 | 0.410 |
Why?
|
| Virus Diseases | 2 | 2015 | 398 | 0.400 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 5 | 2017 | 216 | 0.390 |
Why?
|
| Female | 87 | 2023 | 141928 | 0.370 |
Why?
|
| Bone Marrow Transplantation | 5 | 2021 | 1581 | 0.370 |
Why?
|
| Transplantation, Haploidentical | 3 | 2022 | 125 | 0.360 |
Why?
|
| Treatment Outcome | 43 | 2021 | 32848 | 0.360 |
Why?
|
| Remission Induction | 20 | 2022 | 3569 | 0.350 |
Why?
|
| Survival Rate | 24 | 2021 | 12221 | 0.340 |
Why?
|
| Siblings | 3 | 2022 | 285 | 0.330 |
Why?
|
| Bone Marrow | 5 | 2021 | 2358 | 0.320 |
Why?
|
| Hodgkin Disease | 5 | 2017 | 1429 | 0.310 |
Why?
|
| Acute Disease | 8 | 2018 | 2422 | 0.310 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 461 | 0.300 |
Why?
|
| Killer Cells, Natural | 3 | 2018 | 904 | 0.300 |
Why?
|
| Adolescent | 32 | 2024 | 31252 | 0.300 |
Why?
|
| Virus Activation | 3 | 2018 | 228 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 4 | 2009 | 266 | 0.280 |
Why?
|
| Young Adult | 26 | 2021 | 21445 | 0.260 |
Why?
|
| Risk Factors | 20 | 2024 | 17523 | 0.250 |
Why?
|
| Graft Rejection | 2 | 2010 | 834 | 0.250 |
Why?
|
| Lymphoma | 4 | 2019 | 1467 | 0.250 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2022 | 2796 | 0.250 |
Why?
|
| Mycophenolic Acid | 3 | 2022 | 148 | 0.240 |
Why?
|
| Prognosis | 21 | 2022 | 21713 | 0.240 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2017 | 204 | 0.230 |
Why?
|
| Graft Survival | 6 | 2017 | 1062 | 0.230 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2024 | 122 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2017 | 15862 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 2 | 2018 | 462 | 0.210 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2022 | 74 | 0.210 |
Why?
|
| Incidence | 11 | 2024 | 5673 | 0.200 |
Why?
|
| Vascular Diseases | 1 | 2024 | 246 | 0.200 |
Why?
|
| Salvage Therapy | 6 | 2017 | 2054 | 0.190 |
Why?
|
| Neoplasm, Residual | 4 | 2022 | 1656 | 0.190 |
Why?
|
| Neutrophils | 3 | 2017 | 835 | 0.190 |
Why?
|
| Child, Preschool | 11 | 2023 | 16273 | 0.180 |
Why?
|
| Birth Weight | 1 | 2001 | 374 | 0.170 |
Why?
|
| Proportional Hazards Models | 4 | 2023 | 4988 | 0.170 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2018 | 22 | 0.170 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2018 | 31 | 0.160 |
Why?
|
| Follow-Up Studies | 16 | 2021 | 14889 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 1350 | 0.160 |
Why?
|
| Blood Donors | 3 | 2013 | 164 | 0.160 |
Why?
|
| Blood Transfusion | 1 | 2021 | 583 | 0.160 |
Why?
|
| Blast Crisis | 1 | 2021 | 557 | 0.160 |
Why?
|
| Donor Selection | 2 | 2022 | 110 | 0.150 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2013 | 713 | 0.150 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 669 | 0.150 |
Why?
|
| Pentostatin | 1 | 2017 | 119 | 0.150 |
Why?
|
| Leukapheresis | 3 | 2013 | 152 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2021 | 677 | 0.150 |
Why?
|
| Hepatitis B Antibodies | 1 | 2017 | 58 | 0.150 |
Why?
|
| Fetal Blood | 2 | 2017 | 482 | 0.150 |
Why?
|
| Cystitis | 2 | 2010 | 107 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2009 | 749 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 2 | 2017 | 589 | 0.140 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 482 | 0.130 |
Why?
|
| Chromosome Aberrations | 2 | 2020 | 1960 | 0.130 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 1664 | 0.130 |
Why?
|
| Infliximab | 3 | 2011 | 130 | 0.130 |
Why?
|
| Seizures | 1 | 2001 | 989 | 0.130 |
Why?
|
| Photopheresis | 2 | 2006 | 79 | 0.130 |
Why?
|
| Lymphoma, Follicular | 2 | 2012 | 587 | 0.130 |
Why?
|
| Cohort Studies | 6 | 2020 | 9244 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 3552 | 0.130 |
Why?
|
| Combined Modality Therapy | 12 | 2020 | 8865 | 0.130 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2015 | 109 | 0.130 |
Why?
|
| Lymphocyte Transfusion | 2 | 2013 | 175 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 324 | 0.120 |
Why?
|
| Outpatients | 1 | 2017 | 462 | 0.120 |
Why?
|
| Risk | 2 | 2017 | 1972 | 0.120 |
Why?
|
| Child | 16 | 2022 | 29154 | 0.120 |
Why?
|
| Myeloproliferative Disorders | 1 | 2021 | 767 | 0.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 1021 | 0.120 |
Why?
|
| Ganciclovir | 1 | 2013 | 174 | 0.110 |
Why?
|
| Blood Volume | 1 | 2013 | 100 | 0.110 |
Why?
|
| SOXC Transcription Factors | 1 | 2013 | 53 | 0.110 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2013 | 37 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2015 | 176 | 0.110 |
Why?
|
| Mortality | 1 | 2015 | 343 | 0.110 |
Why?
|
| Antigens, Viral | 1 | 2015 | 471 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 7 | 2013 | 864 | 0.110 |
Why?
|
| Deoxycytidine | 2 | 2016 | 1353 | 0.110 |
Why?
|
| Prospective Studies | 8 | 2018 | 12873 | 0.110 |
Why?
|
| Inpatients | 1 | 2017 | 678 | 0.100 |
Why?
|
| Leukocyte Transfusion | 1 | 2012 | 43 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2013 | 272 | 0.100 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2017 | 801 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 361 | 0.100 |
Why?
|
| Alleles | 2 | 2015 | 2437 | 0.100 |
Why?
|
| Patient Selection | 2 | 2017 | 2055 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 402 | 0.100 |
Why?
|
| Antineoplastic Agents | 8 | 2009 | 14289 | 0.100 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 666 | 0.100 |
Why?
|
| B-Lymphocytes | 2 | 2015 | 1294 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 4298 | 0.100 |
Why?
|
| Thalidomide | 2 | 2017 | 569 | 0.100 |
Why?
|
| Transplantation Chimera | 4 | 2015 | 155 | 0.090 |
Why?
|
| Rituximab | 7 | 2013 | 1528 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 115 | 0.090 |
Why?
|
| Steroids | 3 | 2020 | 356 | 0.090 |
Why?
|
| Blood Platelets | 2 | 2012 | 731 | 0.090 |
Why?
|
| Vitamin D | 1 | 2011 | 261 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2011 | 241 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 2 | 2009 | 602 | 0.080 |
Why?
|
| BK Virus | 1 | 2010 | 123 | 0.080 |
Why?
|
| Polyomavirus Infections | 1 | 2010 | 139 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2006 | 1039 | 0.080 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 3719 | 0.080 |
Why?
|
| Body Weight | 1 | 2013 | 1293 | 0.080 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 224 | 0.080 |
Why?
|
| Leukemia | 2 | 2010 | 1635 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 2008 | 131 | 0.080 |
Why?
|
| Models, Biological | 1 | 2017 | 3254 | 0.080 |
Why?
|
| Oxides | 1 | 2008 | 211 | 0.080 |
Why?
|
| Arsenicals | 1 | 2008 | 201 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10035 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2010 | 546 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2020 | 6100 | 0.080 |
Why?
|
| Translocation, Genetic | 1 | 2013 | 1245 | 0.080 |
Why?
|
| Holmium | 1 | 2007 | 23 | 0.080 |
Why?
|
| Philadelphia Chromosome | 1 | 2011 | 793 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2013 | 1242 | 0.070 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2007 | 102 | 0.070 |
Why?
|
| Thiotepa | 3 | 2013 | 118 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2010 | 258 | 0.070 |
Why?
|
| Leukocyte Count | 1 | 2008 | 684 | 0.070 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 4892 | 0.070 |
Why?
|
| Organophosphorus Compounds | 1 | 2007 | 101 | 0.070 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2007 | 105 | 0.070 |
Why?
|
| Erythroid Precursor Cells | 1 | 2006 | 61 | 0.070 |
Why?
|
| Stroke Volume | 1 | 2009 | 577 | 0.070 |
Why?
|
| Blood Cells | 1 | 2006 | 127 | 0.070 |
Why?
|
| Radioisotopes | 1 | 2007 | 177 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 321 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2013 | 1230 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 327 | 0.070 |
Why?
|
| Hepacivirus | 1 | 2009 | 397 | 0.070 |
Why?
|
| Autografts | 2 | 2017 | 165 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2009 | 703 | 0.070 |
Why?
|
| Leukemia, Myeloid | 1 | 2010 | 941 | 0.070 |
Why?
|
| Antioxidants | 1 | 2008 | 507 | 0.070 |
Why?
|
| Whole-Body Irradiation | 3 | 2017 | 307 | 0.070 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2005 | 72 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 6207 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2006 | 345 | 0.060 |
Why?
|
| Disease Progression | 5 | 2017 | 6682 | 0.060 |
Why?
|
| Graft vs Tumor Effect | 3 | 2012 | 139 | 0.060 |
Why?
|
| Vincristine | 2 | 2009 | 1511 | 0.060 |
Why?
|
| Hemorrhagic Disorders | 1 | 2004 | 51 | 0.060 |
Why?
|
| Time Factors | 6 | 2020 | 12926 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 186 | 0.060 |
Why?
|
| Dexamethasone | 2 | 2009 | 1450 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2007 | 2390 | 0.060 |
Why?
|
| Blood Cell Count | 2 | 2013 | 225 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2009 | 732 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 1005 | 0.050 |
Why?
|
| Age Factors | 3 | 2017 | 5377 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2008 | 1987 | 0.050 |
Why?
|
| Cause of Death | 2 | 2017 | 752 | 0.050 |
Why?
|
| Primary Myelofibrosis | 1 | 2010 | 831 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 2009 | 739 | 0.050 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2020 | 29 | 0.050 |
Why?
|
| Biopsy | 2 | 2020 | 3443 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2009 | 3005 | 0.050 |
Why?
|
| Ferritins | 1 | 2021 | 151 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2020 | 2292 | 0.050 |
Why?
|
| Cardiotoxicity | 1 | 2021 | 155 | 0.050 |
Why?
|
| Etoposide | 3 | 2009 | 870 | 0.050 |
Why?
|
| Infant, Low Birth Weight | 1 | 2001 | 181 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1323 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2006 | 1048 | 0.050 |
Why?
|
| Receptors, Cytokine | 1 | 2021 | 176 | 0.050 |
Why?
|
| Azithromycin | 1 | 2020 | 78 | 0.050 |
Why?
|
| Chronic Disease | 4 | 2006 | 1819 | 0.040 |
Why?
|
| Mothers | 1 | 2022 | 410 | 0.040 |
Why?
|
| Butyrophenones | 1 | 2019 | 12 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 2173 | 0.040 |
Why?
|
| Stem Cells | 1 | 2006 | 1213 | 0.040 |
Why?
|
| Infant, Premature, Diseases | 1 | 2001 | 245 | 0.040 |
Why?
|
| Methotrexate | 1 | 2022 | 999 | 0.040 |
Why?
|
| Antigens, CD34 | 2 | 2013 | 593 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2018 | 60 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 568 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1538 | 0.040 |
Why?
|
| Immunologic Factors | 2 | 2016 | 649 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2003 | 1033 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2005 | 895 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 324 | 0.040 |
Why?
|
| Filgrastim | 2 | 2009 | 191 | 0.040 |
Why?
|
| Gestational Age | 1 | 2001 | 1069 | 0.040 |
Why?
|
| Recombinant Proteins | 3 | 2009 | 2927 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2018 | 2803 | 0.040 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2017 | 86 | 0.040 |
Why?
|
| Monosomy | 1 | 2017 | 95 | 0.040 |
Why?
|
| Ifosfamide | 2 | 2009 | 344 | 0.040 |
Why?
|
| Survivors | 3 | 2007 | 1031 | 0.040 |
Why?
|
| Myeloma Proteins | 1 | 2015 | 28 | 0.030 |
Why?
|
| Texas | 2 | 2012 | 6311 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2001 | 787 | 0.030 |
Why?
|
| Premedication | 1 | 2016 | 135 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 344 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 4757 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2003 | 1586 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 2015 | 74 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2018 | 829 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 2232 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 231 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 375 | 0.030 |
Why?
|
| Cell Separation | 1 | 2017 | 612 | 0.030 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10331 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 446 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 452 | 0.030 |
Why?
|
| Immunosuppressive Agents | 3 | 2006 | 1375 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 1382 | 0.030 |
Why?
|
| Nausea | 1 | 2016 | 525 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 29902 | 0.030 |
Why?
|
| Cytarabine | 2 | 2013 | 1973 | 0.030 |
Why?
|
| Cytogenetics | 1 | 2013 | 149 | 0.030 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2012 | 37 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 4320 | 0.030 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 426 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2016 | 349 | 0.030 |
Why?
|
| Human Experimentation | 1 | 2013 | 51 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2016 | 279 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2017 | 574 | 0.030 |
Why?
|
| Radioimmunotherapy | 1 | 2012 | 119 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2016 | 1442 | 0.020 |
Why?
|
| Yttrium Radioisotopes | 1 | 2012 | 178 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 257 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 3203 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 194 | 0.020 |
Why?
|
| Transplantation | 1 | 2010 | 56 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 2352 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 3033 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2016 | 717 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 435 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 856 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2012 | 598 | 0.020 |
Why?
|
| Infant | 2 | 2015 | 13310 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3251 | 0.020 |
Why?
|
| Benzylamines | 1 | 2009 | 105 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2009 | 119 | 0.020 |
Why?
|
| Bone Density | 1 | 2011 | 476 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 2008 | 60 | 0.020 |
Why?
|
| Scleroderma, Systemic | 1 | 2009 | 134 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2001 | 8223 | 0.020 |
Why?
|
| Mutation | 2 | 2018 | 15179 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 114 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2008 | 209 | 0.020 |
Why?
|
| Topotecan | 1 | 2008 | 239 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 531 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 884 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 5047 | 0.020 |
Why?
|
| Forms and Records Control | 1 | 2006 | 27 | 0.020 |
Why?
|
| Antigens, CD20 | 1 | 2006 | 206 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1546 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2006 | 238 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2009 | 1391 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2010 | 712 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 216 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1537 | 0.020 |
Why?
|
| Carmustine | 1 | 2005 | 214 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 980 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2006 | 332 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2005 | 334 | 0.020 |
Why?
|
| Medical Records | 1 | 2006 | 415 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 543 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 2005 | 214 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 447 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2005 | 587 | 0.020 |
Why?
|
| Aging | 1 | 2013 | 1582 | 0.020 |
Why?
|
| Eye | 1 | 2005 | 301 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 1756 | 0.010 |
Why?
|
| Patients | 1 | 2006 | 245 | 0.010 |
Why?
|
| Data Collection | 1 | 2006 | 620 | 0.010 |
Why?
|
| Ischemia | 1 | 2006 | 391 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 2049 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 665 | 0.010 |
Why?
|
| Forecasting | 1 | 2006 | 694 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2005 | 366 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 297 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 1301 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2006 | 544 | 0.010 |
Why?
|
| Neoplasms | 2 | 2006 | 15193 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 1226 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 1382 | 0.010 |
Why?
|
| Anemia, Sickle Cell | 1 | 2005 | 339 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 486 | 0.010 |
Why?
|
| United States | 2 | 2011 | 15433 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2004 | 403 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1248 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 2315 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 2359 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 846 | 0.010 |
Why?
|
| Mycoses | 1 | 2004 | 386 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 13658 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2004 | 479 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 1259 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 1544 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2005 | 1411 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 3260 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 2961 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2005 | 5687 | 0.010 |
Why?
|
| Animals | 2 | 2009 | 59536 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 34495 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 15694 | 0.000 |
Why?
|